ArticleJournal of ovarian research2026
Biological consistency and molecular heterogeneity in synchronous endometrial and ovarian carcinomas: a clinicopathological study within the FIGO 2023 framework.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe 2023 International Federation of Gynecology and Obstetrics (FIGO) staging system introduced Stage IA3 to categorize a subset of synchronous endometrial and ovarian carcinomas (SEOC) with favorable outcomes. This study aims to evaluate the clinical and biological rationale of the FIGO 2023 Stage IA3 criteria by analyzing paired molecular profiles and assessing the prognostic impact of ovarian versus endometrial clinicopathological features.
methodsA retrospective cohort of 48 SEOC patients was evaluated and stratified into three cohorts: Group A (Stage IA3, n = 12), Group B (Advanced Concordant, n = 26), and Group C (Independent Discordant, n = 10). Survival outcomes were assessed alongside clinical interventions. Given the retrospective design, clonal relationships were assessed in a sub-cohort of 17 patients for whom complete paired immunohistochemistry (IHC) data for mismatch repair (MMR) proteins and p53 were available for both tumor sites.
resultsUnivariate analysis showed that ovarian factors, including histological grade and lymph node metastasis, were significantly associated with overall survival (OS, p < 0.01). In contrast, endometrial parameters, such as myometrial invasion (MI) depth and FIGO stage, did not show statistical significance (all p > 0.5). Group A had a 5-year OS of 90.9%, while Group B showed a 5-year OS of 95.5%, and Group C showed 70.0%. Among the 17 cases with paired IHC testing, molecular discordance was identified in 29.4% (5/17) overall, all of which occurred within the non-IA3 group, yielding a discordance rate of 38.5% (5/13 in non-IA3 group vs. 0% in Stage IA3 group). Notably, Case 29 exhibited concordant p53 mutational patterns but divergent MMR status between the endometrial and ovarian lesions.
conclusionIn conclusion, our preliminary findings suggest that the FIGO 2023 Stage IA3 classification defines a biologically consistent, low-risk cohort, offering a potential rationale for exploring future treatment de-escalation. Furthermore, paired molecular profiling (p53 and MMR) highlights the value of assessing tumor heterogeneity and clonal evolution for refined risk stratification. Clinical management may benefit from integrating molecular risk features to better distinguish true concordant SEOC from independent aggressive malignancies, particularly in histologically discordant cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.